What is the recommended dose and frequency of Ceftin (Cefuroxime) for treating urinary tract infections (UTI)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Cefuroxime (Ceftin) Dosing for Urinary Tract Infections

For urinary tract infections, the recommended dose of Cefuroxime (Ceftin) is 750 mg administered every 8 hours intravenously for 5-10 days in uncomplicated UTIs. 1

Dosing Recommendations

Intravenous (IV) Administration

  • Uncomplicated UTIs: 750 mg every 8 hours 1
  • Severe or complicated UTIs: 1.5 grams every 8 hours 1
  • Typical treatment duration: 5-10 days 1

Oral Administration (Cefuroxime Axetil)

  • For most UTIs: 250 mg twice daily 2
  • For some uncomplicated UTIs: 125 mg twice daily may be effective 2
  • For more severe infections: 500 mg twice daily 2

Dosage Adjustment for Renal Impairment

Cefuroxime requires dose adjustment based on creatinine clearance:

  • CrCl >20 mL/min: Standard dose (750 mg - 1.5 grams) every 8 hours
  • CrCl 10-20 mL/min: 750 mg every 12 hours
  • CrCl <10 mL/min: 750 mg every 24 hours (additional dose after hemodialysis) 1

Clinical Considerations

Treatment Selection

While cefuroxime is effective for UTIs, it's important to note that first-line treatment options for uncomplicated UTIs include:

  • Nitrofurantoin
  • Trimethoprim-sulfamethoxazole
  • Fosfomycin 3

Beta-lactams like cefuroxime are generally considered alternative agents rather than first-line therapy for uncomplicated UTIs due to potentially inferior efficacy or more adverse effects 3.

Treatment Duration

  • Continue treatment for a minimum of 48-72 hours after the patient becomes asymptomatic
  • For chronic UTIs, frequent clinical and bacteriological assessment is necessary and may require several months of follow-up 1

Special Populations

  • Pediatric patients (>3 months): 50-100 mg/kg/day divided every 6-8 hours
  • Severe pediatric infections: 100 mg/kg/day (not exceeding maximum adult dosage) 1

Monitoring

  • No routine laboratory monitoring is required for short-course therapy 3
  • For chronic UTIs, regular bacteriological and clinical assessment is recommended 1

Common Side Effects

  • Gastrointestinal disturbances (diarrhea, nausea, vomiting) 2
  • When using oral cefuroxime axetil, dividing the daily dose into two administrations may reduce gastrointestinal adverse effects compared to once-daily dosing 4

Clinical Pearl

A study has shown that a single daily dose of 250 mg cefuroxime axetil for 10 days can be effective for acute uncomplicated UTIs, with 95% of patients having clear urine during treatment and an overall cure rate of 86% 5. However, the standard twice-daily dosing is more commonly recommended and supported by the drug label.

References

Research

Cefuroxime axetil.

International journal of antimicrobial agents, 1994

Guideline

Treatment of Urinary Tract Infections

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.